BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 36630607)

  • 41. Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects.
    Tsuyama N; Sakamoto K; Sakata S; Dobashi A; Takeuchi K
    J Clin Exp Hematop; 2017; 57(3):120-142. PubMed ID: 29279550
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma.
    Subbiah V; Kuravi S; Ganguly S; Welch DR; Vivian CJ; Mushtaq MU; Hegde A; Iyer S; Behrang A; Ali SM; Madison RW; Venstrom JM; Jensen RA; McGuirk JP; Amin HM; Balusu R
    ESMO Open; 2021 Aug; 6(4):100172. PubMed ID: 34242968
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Analysis and therapeutic targeting of the IL-1R pathway in anaplastic large cell lymphoma.
    Song Z; Wu W; Wei W; Xiao W; Lei M; Cai KQ; Huang DW; Jeong S; Zhang JP; Wang H; Kadin ME; Waldmann TA; Staudt LM; Nakagawa M; Yang Y
    Blood; 2023 Oct; 142(15):1297-1311. PubMed ID: 37339580
    [TBL] [Abstract][Full Text] [Related]  

  • 44. ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.
    Lovisa F; Cozza G; Cristiani A; Cuzzolin A; Albiero A; Mussolin L; Pillon M; Moro S; Basso G; Rosolen A; Bonvini P
    PLoS One; 2015; 10(4):e0121378. PubMed ID: 25874976
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1).
    Marzec M; Zhang Q; Goradia A; Raghunath PN; Liu X; Paessler M; Wang HY; Wysocka M; Cheng M; Ruggeri BA; Wasik MA
    Proc Natl Acad Sci U S A; 2008 Dec; 105(52):20852-7. PubMed ID: 19088198
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death.
    Zamo A; Chiarle R; Piva R; Howes J; Fan Y; Chilosi M; Levy DE; Inghirami G
    Oncogene; 2002 Feb; 21(7):1038-47. PubMed ID: 11850821
    [TBL] [Abstract][Full Text] [Related]  

  • 47. EBP2, a novel NPM-ALK-interacting protein in the nucleolus, contributes to the proliferation of ALCL cells by regulating tumor suppressor p53.
    Uchihara Y; Tago K; Tamura H; Funakoshi-Tago M
    Mol Oncol; 2021 Jan; 15(1):167-194. PubMed ID: 33040459
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The high-mobility group A1a/signal transducer and activator of transcription-3 axis: an achilles heel for hematopoietic malignancies?
    Hillion J; Dhara S; Sumter TF; Mukherjee M; Di Cello F; Belton A; Turkson J; Jaganathan S; Cheng L; Ye Z; Jove R; Aplan P; Lin YW; Wertzler K; Reeves R; Elbahlouh O; Kowalski J; Bhattacharya R; Resar LM
    Cancer Res; 2008 Dec; 68(24):10121-7. PubMed ID: 19074878
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.
    Christensen JG; Zou HY; Arango ME; Li Q; Lee JH; McDonnell SR; Yamazaki S; Alton GR; Mroczkowski B; Los G
    Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3314-22. PubMed ID: 18089725
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma.
    Han Y; Amin HM; Franko B; Frantz C; Shi X; Lai R
    Blood; 2006 Oct; 108(8):2796-803. PubMed ID: 16825495
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphoma.
    Bard JD; Gelebart P; Anand M; Amin HM; Lai R
    Leukemia; 2008 Aug; 22(8):1595-603. PubMed ID: 18509351
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular characterization of the t(2;5) (p23; q35) translocation in anaplastic large cell lymphoma (Ki-1) and Hodgkin's disease.
    Yee HT; Ponzoni M; Merson A; Goldstein M; Scarpa A; Chilosi M; Menestrina F; Pittaluga S; de Wolf-Peeters C; Shiota M; Mori S; Frizzera G; Inghirami G
    Blood; 1996 Feb; 87(3):1081-8. PubMed ID: 8562933
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes.
    Laurent C; Delas A; Gaulard P; Haioun C; Moreau A; Xerri L; Traverse-Glehen A; Rousset T; Quintin-Roue I; Petrella T; Emile JF; Amara N; Rochaix P; Chenard-Neu MP; Tasei AM; Menet E; Chomarat H; Costes V; Andrac-Meyer L; Michiels JF; Chassagne-Clement C; de Leval L; Brousset P; Delsol G; Lamant L
    Ann Oncol; 2016 Feb; 27(2):306-14. PubMed ID: 26598546
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cellular and Molecular Mechanisms of Breast Implant-Associated Anaplastic Large Cell Lymphoma.
    DeCoster RC; Clemens MW; Di Napoli A; Lynch EB; Bonaroti AR; Rinker BD; Butterfield TA; Vasconez HC
    Plast Reconstr Surg; 2021 Jan; 147(1):30e-41e. PubMed ID: 33370049
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Unusual childhood extramedullary hematologic malignancy with natural killer cell properties that contains tropomyosin 4--anaplastic lymphoma kinase gene fusion.
    Meech SJ; McGavran L; Odom LF; Liang X; Meltesen L; Gump J; Wei Q; Carlsen S; Hunger SP
    Blood; 2001 Aug; 98(4):1209-16. PubMed ID: 11493472
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma.
    Merkel O; Hamacher F; Laimer D; Sifft E; Trajanoski Z; Scheideler M; Egger G; Hassler MR; Thallinger C; Schmatz A; Turner SD; Greil R; Kenner L
    Proc Natl Acad Sci U S A; 2010 Sep; 107(37):16228-33. PubMed ID: 20805506
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma.
    Zhang Q; Raghunath PN; Xue L; Majewski M; Carpentieri DF; Odum N; Morris S; Skorski T; Wasik MA
    J Immunol; 2002 Jan; 168(1):466-74. PubMed ID: 11751994
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Large Granular Lymphocytic Leukemia and JAK/STAT Signaling Pathway--Review].
    Qiu ZY; Fan Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):254-60. PubMed ID: 26913432
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3.
    Marzec M; Kasprzycka M; Ptasznik A; Wlodarski P; Zhang Q; Odum N; Wasik MA
    Lab Invest; 2005 Dec; 85(12):1544-54. PubMed ID: 16170336
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.
    Boi M; Todaro M; Vurchio V; Yang SN; Moon J; Kwee I; Rinaldi A; Pan H; Crescenzo R; Cheng M; Cerchietti L; Elemento O; Riveiro ME; Cvitkovic E; Bertoni F; Inghirami G;
    Oncotarget; 2016 Nov; 7(48):79637-79653. PubMed ID: 27793034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.